Market Size and Growth Outlook
The Non-invasive Prenatal Testing market is expected to grow significantly, rising from USD 5.74 billion in 2024 to over USD 19.36 billion by 2035. It reached around USD 6.41 billion in 2025 and is expected to expand at a CAGR of 11.69% during the forecast period from 2025 to 2035.
Key Report Highlights
The non-invasive prenatal testing (NIPT) market includes products and services that analyse cell free fetal DNA from maternal blood to detect chromosomal abnormalities such as trisomy 21, 18, 13 and sex chromosome disorders using advanced sequencing and data analysis technologies. Market growth is driven by rising maternal age and increasing awareness of early genetic screening, along with technological advancements that improve accuracy and speed while reducing the need for invasive procedures and lowering the risk of miscarriage. The integration of AI, machine learning and bioinformatics in cell free fatal DNA analysis enhances the accuracy and speed of detecting chromosomal abnormalities, reduces false positive and false negative results and improves overall risk assessment by combining genomic data with clinical parameters.
Increasing maternal age in both developed and emerging economies is raising the risk of chromosomal abnormalities such as trisomy 21, 18, and 13, which is driving higher demand for NIPT for early fetal screening using cell free DNA analysis. According to the OECD, the average of women at childbirth is at least 30 in most member countries and exceeds 32 in nations such as Greece, Italy, Japan, south Korea, Spain and Switzerland further supporting the growth of the NIPT market. The integration of AI and advanced bioinformatics in NIPT is creating significant growth opportunities by improving genomic data interpretation, increasing detection accuracy and enabling machine learning models is to identify rare chromosomal abnormalities from large scale sequencing data.
On the basis of gestation period, the 0–12-week segment accounted for the largest market share due to increasing preference for early fetal screening, improved accuracy of cell free DNA testing and rising recommendations for first trimester prenatal screening, while the 13–24-week segment is expected to witness the fastest growth owing to increasing use of confirmatory an combined screening tests during the second trimester. By pregnancy risk, high & average risk represented the highest revenue because of their high probability of chromosomal abnormalities, growing maternal age and favourable physician recommendations, whereas the low-risk segment is projected to grow rapidly due to expanding universal screening practices and increasing confidence in NIPT accuracy and safety. By method, cell free DNA in maternal plasma tests held the largest revenue share in 2024 as they provide highly accurate, non-invasive and efficient screening for chromosomal disorders, while biochemical screening tests are expected to grow steadily because of their affordability and continued use on public healthcare systems. By technology, NGS dominated the market with 48.8% share due to its high analytical precision, scalability and ability to detect multiple chromosomal abnormalities simultaneously, while PCR technology is anticipated to witness noticeable growth because of faster turnaround time, lower capital investment and improving assay sensitivity. Based on product, consumables & reagents accounted for the highest market share due to recurring demand for testing kits and sample preparation material in every prenatal test whereas instruments are expected to grow steadily with increasing investments in laboratory automation and molecular diagnostic infrastructure. Based on application, the trisomy segment led the market owing to strong clinical focus on detecting conditions such as down syndrome Trisomy 18 and Trisomy 13, with the microdeletion syndrome segment is projected to expand rapidly due to growing adoption of expanded NIPT panels and advanced sequencing technologies. By end use, diagnostic laboratory held the largest market share because of their advanced sequencing capabilities, skilled personnel and high throughput testing capacities, while hospitals and clinics are expected to register steady growth with the expansion of in house molecular diagnostic services and integrated prenatal care programs.
North America held the largest market share of 40.37% valued at USD 2.32 billion and is projected to reach USD 7.82 billion by 2035 driven by rising maternal age, strong awareness of early fetal chromosomal screening and increasing adoption of cell free DNA based NIPT in the US and Canada. Asia pacific is expected to register the highest CAGR during the forecast period due to high birth rates, growing middle class healthcare spending and expanding access to private maternity hospitals and diagnostic laboratories, particularly in countries such as India. The European market is supported by well-established pre-natal screening programs in countries including Germany, France and the UK along with growing integration of non-invasive prenatal tests into public healthcare systems for high-risk pregnancies. Market growth in Latin America is driven by the expansion of private diagnostic laboratories and rising maternal age in Brazil and Mexico, while the middle east and Africa region is benefitting from healthcare infrastructure investments and increasing availability of specialised prenatal diagnostic centres in countries such as the UAE, Saudi Arabia and South Africa.
Non-invasive Prenatal Testing Market Trends
- The increasing maternal age across developed and emerging countries is raising the risk of chromosomal abnormalities such as trisomy 21, 18 and 13, thereby strengthening demand for early prenatal genetic screening.
- Growing awareness regarding the benefits of non-invasive prenatal testing, including early fetal health assessment and reduced miscarriage risk compared to invasive procedures, is supporting wider patient acceptance and adoption.
- Rising investments in molecular diagnostic infrastructure, automated laboratory workflow and specialised prenatal diagnostic centers are supporting market growth across developed and emerging regions.
- Increasing use of expanded genetic panels for detection of microdeletion syndromes and rare chromosomal abnormalities is broader clinical applications of NIPT.
- Growing preference for non-invasive diagnostic methods over invasive procedures is reducing miscarriage risks and increasing patient acceptance.
List of key players in Non-invasive Prenatal Testing Market:
- Illumina, Inc. – US
- Natera, Inc. – US
- Hoffmann-La Roche Ltd. – Switzerland
- BGI Genomics Co., Ltd. – China
- Laboratory Corporation of America Holdings – US
- Quest Diagnostics Incorporated – US
- Eurofins LifeCodexx GmbH – Germany
- Berry Genomics Co., Ltd. – China
- Myriad Genetics, Inc. – US
- Agilent Technologies, Inc. – US
Non-invasive Prenatal Testing Market Segmentation
The NIPT market can be segmented on the basis of gestation period, pregnancy risk, method, technology, product, application and end use:
Non-invasive Prenatal Testing Market Gestation Period Outlook, Revenue (USD Billion) (2025-2035)
- 0-12 Weeks
- 13-24 Weeks
- 25-36 Weeks
Non-invasive Prenatal Testing Market Pregnancy Risk Outlook, Revenue (USD Billion) (2025-2035)
- High & Average Risk
- Low Risk
Non-invasive Prenatal Testing Market Method Outlook, Revenue (USD Billion) (2025-2035)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-free DNA in Maternal Plasma Tests
Non-invasive Prenatal Testing Market Technology Outlook, Revenue (USD Billion) (2025-2035)
- NGS
- Array Technology
- PCR
- Others
Non-invasive Prenatal Testing Market Product Outlook, Revenue (USD Billion) (2025-2035)
- Consumables & Reagents
- Instruments
Non-invasive Prenatal Testing Market Application Outlook, Revenue (USD Billion) (2025-2035)
- Trisomy
- Microdeletion Syndrome
- Other Applications
Non-invasive Prenatal Testing Market End Use Outlook, Revenue (USD Billion) (2025-2035)
- Hospitals & Clinics
- Diagnostic Laboratories
Non-invasive Prenatal Testing Market Regional Outlook, Revenue (USD Billion) (2025-2035)
- North America
- Canada
- Mexico
- U.S.
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Europe
- Germany
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Latin America
- Argentina
- Brazil
- Chile
- Middle East and Africa
- GCC
- Turkey
- South Africa